Abbott: Patients on Xience V less likely to suffer heart attack

Abbott has highlighted the results of the Spirit III trial, which revealed the company’s Xience V reduces the risk of heart attack in patients.

The everolimus eluting coronary stent system was found to lower the chance of a major adverse cardiac event by 45 per cent after two years, when compared to Taxus.

Results from the study of 1,002 patients – published in the journal Circulation – also revealed the product demonstrated a 40 per cent reduction in the risk of heart attack of cardiac death over the same period.

The threat of target vessel failure was lessened by 32 per cent.

Gregg Stone, principal investigator of the study, said the results demonstrated the “clinical benefits” of the product.

“These data reinforce our earlier findings demonstrating the excellent angiographic and clinical results with the Xience V stent, resulting in fewer heart attacks and repeat reinterventions,” he added.

In October last year, the product received a 2008 Chicago Innovation Award.

Abbott explained the win was based on the treatment’s design and clinical data.